Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience.

Journal Article (Journal Article)

Optimistic results were obtained in the treatment of 39 patients with surgically incurable metastatic malignant melanoma using a regimen including 2 to 3 monthly induction cycles of cis-diamminedichloroplatinum (CDDP), recombinant interleukin-2 (rIL-2) and interferon alpha-2a (IFN alpha-2a). 33 of 39 patients were pretreated with chemotherapy (dacarbazine and/or fotemustine:31, CDDP:6) and 17 of 39 with IFN alpha-2a. Overall response rate was 54% with 13% achieving a complete response for up to 59+ weeks. Moderate to severe side-effects were reversible on rIL-2 cessation and toxicity was manageable in a routine inpatient setting. These results are especially encouraging as they were seen in previously treated patients, classically low responders, including 3 who were resistant to cisplatin or other platinum complexes. The question remains if this regimen bypasses traditional mechanisms of drug resistance.

Full Text

Duke Authors

Cited Authors

  • Khayat, D; Antoine, E; Rixe, O; Tourani, JM; Vuillemin, E; Borel, C; Benhammouda, A; Thill, L; Franks, C; Auclerc, G

Published Date

  • 1993

Published In

Volume / Issue

  • 29A Suppl 5 /

Start / End Page

  • S2 - S5

PubMed ID

  • 8260262

International Standard Serial Number (ISSN)

  • 0959-8049

Digital Object Identifier (DOI)

  • 10.1016/0959-8049(93)90616-n


  • eng

Conference Location

  • England